Targeted therapy in first line treatment of RAS wild type colorectal cancer

World Journal of Gastroenterology : WJG
Vincenzo Formica, Mario Roselli

Abstract

The debate on the optimal drug combination for treating chemotherapy-naïve patients with metastatic colorectal cancer has recently become particularly heated. The present editorial will review recent data on this topic. The FIRE-3 and PEAK trials have shown a 7.5 to 12 mo survival advantage with the use anti-epidermal growth factor receptor (anti-EGFR) antibodies. The CALGB 80405 has shown no difference between anti-EGFR and anti-vascular endothelial growth factor agents. All three trials have consistently shown a significant increase in objective response rate. These data suggest that there is a subset of metastatic colorectal cancer patients, rigorously selected by molecular profiling, who particularly benefit from an anti-EGFR-based regimen in the first-line setting.

References

May 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthias HoldhoffLuis A Diaz
Jul 19, 2011·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Emmanuelle NorguetJean-François Seitz
Jan 22, 2013·International Journal of Cancer. Journal International Du Cancer·Sandra HeskampHanneke W M van Laarhoven
Aug 5, 2014·The Lancet Oncology·Francesco Sclafani, David Cunningham
Aug 27, 2014·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·A CurrieR Kennedy
Sep 16, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Christopher N GrahamBeth Barber
Sep 26, 2014·World Journal of Gastroenterology : WJG·Vincenzo FormicaMario Roselli

❮ Previous
Next ❯

Citations

Jun 17, 2015·Expert Opinion on Drug Safety·Mercedes Salgado FernándezMarta García de la Torre
Jan 27, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Haixing WangYingyong Hou
Mar 2, 2016·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Elie KassoufMustapha Tehfe
May 28, 2019·Cancer Causes & Control : CCC·Johnie RoseNeal J Meropol

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.